Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a community mental health centre

Tarricone, Ilaria; Casoria, Michela; Gozzi, Beatrice Ferrari; Grieco, Daniela; Menchetti, Marco; Serretti, Alessandro; Ujkaj, Manjola; Pastorelli, Francesca; Berardi, Domenico
January 2006
BMC Psychiatry;2006, Vol. 6, p11
Academic Journal
Background: Second generation antipsychotics (SGA) have demonstrated several advantages over first generation antipsychotics (FGA) in terms of positive, negative, cognitive, and affective symptoms and a lower propensity for extrapyramidal side effects. Despite these undeniable advantages, SGA have been associated with causing and exacerbating metabolic disorders, such as obesity, diabetes, and hyperlipidemia. This cross sectional study aimed to evaluate the metabolic risk factor profile associated with use of SGAs in comparison with non-treated control patients. Methods: The study was carried out at a Community Mental Health Centre (CMHC) in Bologna. The study subjects were outpatients with serious mental disorders treated with SGA (clozapine, olanzapine, risperidone, quetiapine). A sample of adult men and women suffering from idiopathic hyperhydrosis, without psychiatric history or antipsychotic treatment, were randomly selected from outpatients of the Department of Neurology in Bologna as a reference group. We investigated differences among the treatment and reference groups for glycaemia, cholesterolaemia and triglyceridaemia levels. Results: The study sample was composed of 76 patients, 38 males and 38 females. The reference group was composed of 36 subjects, 19 females and 17 males. All patients treated with SGAs had higher mean glycaemia and triglyceridaemia and a significantly higher risk of receiving a diagnosis of hyperglycaemia and hypertriglyceridaemia than the reference group. We did not find any differences in mean glycaemia or mean triglyceridaemia levels among treatment groups. Patients with clozapine had a significantly higher mean BMI value and rate of obesity than patients treated with other SGAs. Conclusion: The rate of obesity and metabolic disorders observed in this study were higher than the prevalence in the control group and similar to that previously reported in psychiatric samples; these findings imply per se that more attention should be paid to the metabolic condition of psychiatric patients. In line with the International Consensus Conferences we recommend that monitoring of weight, fasting plasma glucose, cholesterol and triglyceride levels be obtained in routine clinical practice with all antipsychotics.


Related Articles

  • Yeni KuÅŸak Antipsikotiklerin Metabolik Yan Etkileri. Mete, Levent; Ünsal, Pinar Çetinay // Klinik Psikofarmakoloji Bulteni;Sep2004, Vol. 14 Issue 3, p168 

    With the introduction of atypical antipsychotics, a promising new era in the treatment of schizophrenia and psychotic disorders has begun. These drugs effect a broader range of schizophrenic psychopathology by improving depressive symptomatology and cognitive functions. These drugs are also...

  • A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses. Chagnon, Y. C.; Mérette, C.; Bouchard, R. H.; Émond, C.; Roy, M.-A.; Maziade, M. // Molecular Psychiatry;Dec2004, Vol. 9 Issue 12, p1067 

    Antipsychotics can induce in schizophrenic (SZ) and bipolar disorder (BP) patients serious body weight changes that increase risk for noncompliance to medication, and risk for cardiovascular diseases and diabetes. A genetic origin for this susceptibility to weight changes has been hypothesized...

  • Case Histories Illustrating the Utility of Sertindole in Clinical Practice. Schuck, Peter; Ameele, Hans van den; Jaanson, Peeter; Ryckmans, Vincent; Hawley, Chris // CNS Drugs;2004 Supplement 2, Vol. 18, p31 

    Many conventional and atypical antipsychotic agents are available for the treatment of schizophrenia. Matching individual patients to the medication that suits them best is often a matter of trial and error. Controlled clinical trials and extensive post-marketing research have shown that the...

  • FLUPHENAZINE.  // Davis's Drug Guide for Nurses, 10th edition;2007, p542 

    This article presents a nursing guide to the antipsychotic agent fluphenazine. Drug information provided includes pharmacokinetics, contraindications or precautions, adverse reactions or side effects, interactions, route or dosage, and availability. Popular brands are Modecate, Modecate...

  • Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. Ascher-Svanum, Haya; Baojin Zhu; Faries, Douglas; Landbloom, Ron; Swartz, Marvin; Swanson, Jeff // BMC Psychiatry;2006, Vol. 6, p8 

    Background: There is an ongoing debate over whether atypical antipsychotics are more effective than typical antipsychotics in the treatment of schizophrenia. This naturalistic study compares atypical and typical antipsychotics on time to all-cause medication discontinuation, a recognized index...

  • amisulpride.  // Royal Society of Medicine: Medicines;2002, p52 

    The article provides information on amisulpride, an antipsychotic drug which can be used for the treatment of symptoms of schizophrenia, often in patients who do not respond to, or who can not tolerate, conventional antipsychotic drugs. It is taken orally. Atypical antipsychotics are used with...

  • antipsychotic (Major drug group).  // Royal Society of Medicine: Medicines;2002, p77 

    The article presents information on antipsychotic drugs. These agents calm and soothe patients without impairing consciousness. They are used mainly to treat psychologically disturbed patients, particularly those who manifest the complex behavioral patterns of schizophrenia, and also those with...

  • Clopixol.  // Royal Society of Medicine: Medicines;2002, p162 

    The article presents information on Clopixol, a proprietary, prescription-only preparation of the antipsychotic zuclopenthixol dihydrochloride, and can be used for the long-term maintenance of schizophrenia and other psychoses. It is available as tablets and a depot deep intramuscular injection...

  • loxapine.  // Royal Society of Medicine: Medicines;2002, p342 

    This article presents information on the loxapine, an antipsychotic drug used to treat acute and chronic psychoses. The method of its administration is oral. Some of its side-effects are nausea and vomiting, changes in weight, shortness of breath, drooping of the eyelids, raised body...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics